Randomized Controlled Trial

. 2022 Dec;10(12):1160-1168.

doi: 10.1016/S2213-2600(22)00299-5. Epub 2022 Oct 10.

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

John W Eikelboom¹, Sanjit S Jolly², Emilie P Belley-Cote², Richard P Whitlock³, Sumathy Rangarajan⁴, Lizhen Xu⁴, Laura Heenan⁴, Shrikant I Bangdiwala², Wadea M Tarhuni⁵, Mohamed Hassany⁶, Anna Kontsevaya⁷, William Harper⁸, Sanjib Kumar Sharma⁹, Patricio Lopez-Jaramillo¹⁰, Antonio L Dans¹¹, Lia M Palileo-Villanueva¹¹, Alvaro Avezum¹², Prem Pais¹³, Denis Xavier¹⁴, Camilo Felix¹⁵, Afzalhussein Yusufali¹⁶, Renato D Lopes¹⁷, Otavio Berwanger¹⁸, Zeeshan Ali¹⁹, Sean Wasserman²⁰, Sonia S Anand², Jackie Bosch²¹, Shurjeel Choudhri²², Michael E Farkouh²³, Mark Loeb²⁴, Salim Yusuf²

Affiliations

¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
² Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
³ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Surgery, McMaster University, Hamilton, ON, Canada.
⁴ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada.
⁵ Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Department of Medicine, Western University, Clinical Skills Building London, ON, Canada; Windsor Cardiac Centre, Windsor, ON, Canada.
⁶ National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
⁷ National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
⁸ Department of Medicine, McMaster University, Hamilton, ON, Canada.
⁹ BP Koirala Institute of Health Sciences, Dharan, Nepal.
¹⁰ Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, Colombia.
¹¹ UP College of Medicine, University of the Philippines Manila, Manila, Philippines.
¹² International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
¹³ St John's Research Institute, Bangalore, India.
¹⁴ St John's Medical College, St John's Research Institute, Bangalore, India.
¹⁵ Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador.
¹⁶ Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates.
¹⁷ Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, NC, USA.
¹⁸ Hospital Israelita Albert Einstein, São Paulo, Brazil.
¹⁹ Jinnah Sindh Medical University and Jinnah Postgraduate Medical Center, Karachi, Pakistan.
²⁰ Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
²¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.
²² Bayer, Medical & Scientific Affairs, Mississauga, ON, Canada.
²³ Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada.
²⁴ Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

PMID: 36228639
PMCID: PMC9635862
DOI: 10.1016/S2213-2600(22)00299-5

Randomized Controlled Trial

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

John W Eikelboom et al. Lancet Respir Med. 2022 Dec.

. 2022 Dec;10(12):1160-1168.

doi: 10.1016/S2213-2600(22)00299-5. Epub 2022 Oct 10.

Authors

Affiliations

¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
² Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
³ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; Department of Surgery, McMaster University, Hamilton, ON, Canada.
⁴ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada.
⁵ Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Department of Medicine, Western University, Clinical Skills Building London, ON, Canada; Windsor Cardiac Centre, Windsor, ON, Canada.
⁶ National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
⁷ National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
⁸ Department of Medicine, McMaster University, Hamilton, ON, Canada.
⁹ BP Koirala Institute of Health Sciences, Dharan, Nepal.
¹⁰ Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, Colombia.
¹¹ UP College of Medicine, University of the Philippines Manila, Manila, Philippines.
¹² International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
¹³ St John's Research Institute, Bangalore, India.
¹⁴ St John's Medical College, St John's Research Institute, Bangalore, India.
¹⁵ Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador.
¹⁶ Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates.
¹⁷ Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, NC, USA.
¹⁸ Hospital Israelita Albert Einstein, São Paulo, Brazil.
¹⁹ Jinnah Sindh Medical University and Jinnah Postgraduate Medical Center, Karachi, Pakistan.
²⁰ Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
²¹ Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada; School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.
²² Bayer, Medical & Scientific Affairs, Mississauga, ON, Canada.
²³ Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada.
²⁴ Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

PMID: 36228639
PMCID: PMC9635862
DOI: 10.1016/S2213-2600(22)00299-5

Abstract

Background: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin for prevention of disease progression in community patients with COVID-19.

Methods: The ACT outpatient, open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 clinical sites in 11 countries. Patients in the community aged 30 years and older with symptomatic, laboratory confirmed COVID-19 who were within 7 days of diagnosis and at high risk of disease progression were randomly assigned (1:1) to receive colchicine 0·6 mg twice daily for 3 days and then 0·6 mg once daily for 25 days versus usual care, and in a second (1:1) randomisation to receive aspirin 100 mg once daily for 28 days versus usual care. Investigators and patients were not masked to treatment allocation. The primary outcome was assessed at 45 days in the intention-to-treat population; for the colchicine randomisation it was hospitalisation or death, and for the aspirin randomisation it was major thrombosis, hospitalisation, or death. The ACT outpatient trial is registered at ClinicalTrials.gov, NCT04324463 and is ongoing.

Findings: Between Aug 27, 2020, and Feb 10, 2022, 3917 patients were randomly assigned to colchicine or control and to aspirin or control; after excluding 36 patients due to administrative reasons 3881 individuals were included in the analysis (n=1939 colchicine vs n=1942 control; n=1945 aspirin vs 1936 control). Follow-up was more than 99% complete. Overall event rates were 5 (0·1%) of 3881 for major thrombosis, 123 (3·2%) of 3881 for hospitalisation, and 23 (0·6%) of 3881 for death; 66 (3·4%) of 1939 patients allocated to colchicine and 65 (3·3%) of 1942 patients allocated to control experienced hospitalisation or death (hazard ratio [HR] 1·02, 95% CI 0·72-1·43, p=0·93); and 59 (3·0%) of 1945 of patients allocated to aspirin and 73 (3·8%) of 1936 patients allocated to control experienced major thrombosis, hospitalisation, or death (HR 0·80, 95% CI 0·57-1·13, p=0·21). Results for the primary outcome were consistent in all prespecified subgroups, including according to baseline vaccination status, timing of randomisation in relation to onset of symptoms (post-hoc analysis), and timing of enrolment according to the phase of the pandemic (post-hoc analysis). There were more serious adverse events with colchicine than with control (34 patients [1·8%] of 1939 vs 27 [1·4%] of 1942) but none in either group that led to discontinuation of study interventions. There was no increase in serious adverse events with aspirin versus control (31 [1·6%] vs 31 [1·6%]) and none that led to discontinuation of study interventions.

Interpretation: The results provide no support for the use of colchicine or aspirin to prevent disease progression or death in outpatients with COVID-19.

Funding: Canadian Institutes for Health Research, Bayer, Population Health Research Institute, Hamilton Health Sciences Research Institute, and Thistledown Foundation.

Translations: For the Portuguese, Russian and Spanish translations of the abstract see Supplementary Materials section.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JWE reports grants or in-kind support from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, and Sanofi-Aventis and honoraria from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Merck, Pfizer, Janssen, Sanofi-Aventis, and Servier. SSJ reports grant support from Boston Scientific and consulting fees from Medtronic and Boston Scientific. EPB-C reports grant support from Bayer, Roche, BMS–Pfizer. RPW reports grant support from Bayer, Roche, and BMS-Pfizer, grant and honorarium from Boehringer-Ingelheim, and consultancy fees from Atricure and Phasebio. LMP-V reports ACT study support from Unilab, RiteMed Phils, Philippine Council for Health Research and Development, grant support from Wellcome Trust and Sanofi. AA reports institutional grant support from Bayer and EMS, lecture fees from Bayer, Sanofi-Aventis. DX reports ACT study funding from CIHR, grant support from PHRI, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Coco Cola India, Indian Council of Medical Research, Pfizer, UK Medical Research Council, and Wellcome Trust, speaker fees from Eli Lilly and Sanofi, meeting support from the Indian Council of Medical Research, Eli Lilly, and Sanofi, and leadership roles in SOCHARA and ISCR. RDL reports institutional grant support from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi, consulting fees from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, Sanofi, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck, and Portola, honoraria from Pfizer and meeting travel support from IQVIA. OB reports grant support from Astra Zeneca, Bayer, Amgen, Novartis, Servier, and Pfizer. SW reports grant support from NIH, honoraria from Pfizer, and safety monitoring committee of an AIDS Clinical Trial. SSA reports grants from CIHR and PHAC, honoraria or consulting fees from Bayer, Janssen Pharma, meeting support from Heart and Stroke Canada, committee member at American Heart Association, Canadian Cardiovascular Society, Heart and Stroke Canada. JB reports consulting fees from Bayer. SC reports ACT study funding from Bayer, owns Bayer stock, is a board member of Canadian Arrhythmia Network, is an institutional advisory board member at the Institute of Circulatory and Respiratory Health, Canadian Institutes for Health Research. MEF reports institutional grants from Amgen, Astra Zeneca, Novartis, and Novo Nordisk and consulting fees from Otitopic. ML reports participation in vaccine advisory boards for Medicago, Pfizer, Sanofi, and is on the data safety and monitoring board for CanSino Biologics. SY reports institutional grant support from Bayer and honoraria and travel costs for lectures from Bayer. SR, LX, LH, SIB, WMT, MH, AK, WH, SKS, PL-J, ALD, PP, CF, AY, and ZA have no disclosures to report.

Figures

**Figure 2**
Kaplan-Meier curve showing the effect of colchicine compared with control on the primary outcome of hospitalisation or death

**Figure 3**
Kaplan-Meier curve showing the effect of aspirin compared with control on the primary outcome of major thrombosis, hospitalisation, or death

**Figure 4**
Meta-analysis of randomised trials of colchicine versus control on the trial primary outcome as reported in the trials (A) and mortality (B)

See this image and copyright information in PMC

Comment in

COVID-19: ACT trials for colchicine and antithrombotic therapies.
Barco S, Schreiber K. Barco S, et al. Lancet Respir Med. 2022 Dec;10(12):1106-1108. doi: 10.1016/S2213-2600(22)00368-X. Epub 2022 Oct 10. Lancet Respir Med. 2022. PMID: 36228642 Free PMC article. No abstract available.
In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.
Schectman JM. Schectman JM. Ann Intern Med. 2023 Feb;176(2):JC17. doi: 10.7326/J22-0118. Epub 2023 Feb 7. Ann Intern Med. 2023. PMID: 36745891

References

1. COVID-19 Cumulative Infection Collaborators Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399:2351–2380. - PMC - PubMed
1. COVID-19 Excess Mortality Collaborators Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399:1513–1536. - PMC - PubMed
1. Bollyky TJ, Nuzzo J, Huhn N, Kiernan S, Pond E. Global vaccination must be swifter. Nature. 2022;603:788–792. - PubMed
1. Pavia CS. Pasteur, vaccines, and the refusal to become fully vaccinated in the midst of the COVID-19 pandemic. Front Public Health. 2022;10 - PMC - PubMed
1. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9:622–642. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

VR3-172627/CIHR/Canada

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

Affiliations

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous